Company Overview of Protea Biosciences Group, Inc
Protea Biosciences Group, Inc., molecular information company, develops and commercializes proprietary life science technologies, products, and services to identify the molecules that are produced by living cells and various life forms. The company provides molecular information services for the identification of small and large molecules; and tissue analytics services to create tissue-based molecular profiles. It also offers laser ablation electrospray ionization, a bioanalytical instrument platform that enables the identification of proteins, lipids, and metabolites in tissue, cells, and biofluids, such as serum and urine with minimal or without any sample preparation prior to analysis. It...
955 Hartman Run Road
Morgantown, WV 26507
Founded in 2001
Key Executives for Protea Biosciences Group, Inc
Chairman, Chief Executive Officer and President
Total Annual Compensation: $240.0K
Chief Financial Officer
Total Annual Compensation: $145.6K
Vice President of Operations
Total Annual Compensation: $210.0K
Chief Science Officer and Vice President of Research & Development
Total Annual Compensation: $153.9K
Vice President of Corporate Finance and Development
Total Annual Compensation: $131.0K
Compensation as of Fiscal Year 2014.
Protea Biosciences Group, Inc Key Developments
Protea Biosciences Group, Inc. Announces New Silicon Chip Technology
Jun 1 15
Protea Biosciences Group Inc. announced new, silicon chip technology that enables the rapid identification and quantitation of small molecules in biofluids. The announcement was made at the 63rd American Society of Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics,
held in St. Louis, MO. Known as REDIchip ("Resonance-Enhanced Desorption Ionization"), the product employs a patented, "nanopost array" (NAPA) nanotechnology invented in the laboratory of Prof. Akos Vertes, PhD., Department of Chemistry, The George Washington University, and exclusively licensed to Protea. REDIchip technology was developed by Protea in conjunction with a $14 million DARPA cooperative research agreement led by The George Washington University and including GE Global Research and SRI International. The project goal is to develop new tools to elucidate the mechanism of action of a threat agent, drug, biologic or chemical on living cells within 30 days from exposure. Uncovering the mechanism of action of such agents in 30 days compared to the years currently required will enhance and support the development of effective threat mitigations and countermeasures. REDIchip is formatted as a disposable, single use, 96 spot, target plate, suitable for simple and complex biological mixtures, and compatible with most standard MALDI-MS instrument systems.
Protea Biosciences Group, Inc Announces Board Appointments
Apr 24 15
Effective April 17, 2015, Maged Shenouda and Patrick Gallagher were appointed by the board of directors of Protea Biosciences Group Inc. to serve as directors to fill existing vacancies on the Board. Maged Shenouda has over 25 years of experience in the pharmaceutical and securities industries. Most recently, Mr. Shenouda was the Head of Business Development and Licensing at Retrophin Inc. Patrick Gallagher, CFA, is an accomplished Capital Markets executive, advisor and investor with a distinguished record of success in both the public and private markets with a focus on healthcare, agriculture and industrials. He is a Managing Director and Head of Institutional Sales for Laidlaw & Company (UK) Ltd. Mr. Gallagher sits on the board of directors for BioSig Technologies Inc.
Protea Biosciences Group, Inc Presents at SeeThruEquity 4th Annual MicroCap Investor Conference, May-28-2015 03:30 PM
Apr 22 15
Protea Biosciences Group, Inc Presents at SeeThruEquity 4th Annual MicroCap Investor Conference, May-28-2015 03:30 PM. Venue: Convene Grand Central, 101 Park Ave, New York, NY 10178, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 22, 2015
April 6, 2015
October 31, 2014